Essex-Windsor EMS sees drop in Codes Black as union president warns of staffing and response time issues
The president of CUPE Local 2974, which represents area paramedics, says while the frequency of Codes Black has decreased, any occurrence is too much.
James Jovanovic said Essex-Windsor EMS went into Code Black on Friday night which meant there were no available ambulances to respond to calls in the entirety of the County of Essex.
Jovanovic said during the times when EMS is not in Code Black, there are still issues affecting service.
'Even though we might not be in Code Black, we might only have one or two trucks available in the entirety of the county, so the response time might be anywhere from 30 to 40 minutes,' Jovanovic said.
'Even though Code Black's catch the headlines, we're often strained as a service and response times are extensive.'
Jovanovic said the issue stems from not having the available paramedics needed to fill the allotment of ambulances for patrol.
'Unless we are able to address recruitment, retention, a lack of qualified paramedics in the province as a whole, are ability to compete with other larger services, our inability to compete with other emergency services who are paid approximately 20 per cent higher than EMS across the province, we simply don't stand a chance at being able to compete in that market,' he said.
Jovanovic said Essex-Windsor EMS is in a constant strain of paramedic burnout leading to increased sick time.
'This all adds to the problem of where we are taking ambulances off the road that should otherwise be responding to our community,' Jovanovic said.
'So, unless something long term, and comprehensive is put into place, we're only going to see this problem increase while we have an aging population.'
Jovanovic called upon county council to advocate more for the service as they have direct oversight of Essex-Windsor EMS.
He also called upon all stakeholders, including the provincial government, to come up with a comprehensive approach that addresses recruitment and pay for paramedics.
- Written by Dustin Coffman/AM800 News with files from CTV Windsor's Robert Lothian.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
24 minutes ago
- CTV News
Toronto surgeon dies while competing in triathlon in Barrie
Dr. Sean Cleary is seen in this undated photo released by the University of Toronto. (UofT handout) Members of the city's medical community are mourning the loss of a Toronto surgeon who died while participating in a triathlon in Barrie over the weekend. In a statement released by the University of Toronto, Carol Swallow, the chair of the department of surgery at the post-secondary institution, confirmed that Dr. Sean Cleary, the Langer chair of the division of general surgery, died while taking part in a triathlon north of Toronto on Sunday. 'Sean has touched the lives of many of us – as a clinical colleague, a teacher, a mentor, a supervisor, a confidential advisor, and a friend,' Swallow's statement read. She described the late doctor as a 'reliable, wise, honest, insightful, and compassionate' leader who had a 'perpetually wry sense of humour.' 'I am struggling to accept what has happened,' the statement continued. 'I suspect many of you are feeling a similar sense of shock and denial at this point, and that the profound dimensions of this loss will gradually become apparent over the coming days and weeks.' Barrie police told CP24 Thursday that a 52-year-old man who was taking part in the event was removed from the waters of Kempenfelt Bay shortly after 8:30 a.m. on Sunday after 'going into medical distress.' 'Although lifesaving efforts were initiated, he was pronounced deceased at a local hospital,' police said in an email. A 'shared sense of loss' Swallow said Cleary dedicated much of his professional career to the division of general surgery and the department of surgery at U of T. 'He trained here as a general surgery resident, and then as an HPB (hepatopancreatobiliary) surgical fellow. He graduated from the University of Toronto Surgical Scientist Training Program with an MSc degree in cancer genetics,' Swallow's statement read. 'Straight out of fellowship, Sean was recruited to the University of Toronto Department of Surgery as an Assistant Professor and joined the surgical staff at University Health Network with an appointment as an HPB surgical oncologist at Princess Margaret.' She noted that he developed his own research program in cancer epidemiology and was quickly promoted to associate professor at the university. After leaving for a position at the Mayo Clinic in Rochester, New York in 2016, Cleary returned to Toronto in 2023 to serve as the Bernard and Ryna Langer Chair of the Division of General Surgery at the University of Toronto. 'I wish Sean had had more time to fully deliver on this vision but recognize that much has already been achieved,' Swallow's statement read. She noted that resources are being offered to faculty and learners who are grieving the loss. 'As a surgical family, we express our shared sense of loss and our sincere condolences to Sean's own family,' the statement continued. 'We have all lost a fine human being whose like we will not see again.'
National Post
an hour ago
- National Post
AI with a Heart: Calabrio's CareAI Transforms Patient Care Through Empathy and Intelligence
Article content AI-driven automations of patient interactions could also save healthcare providers up to $1.1 million annually Article content MINNEAPOLIS — Calabrio, the workforce and conversation intelligence company, today announced the expansion of the CareAI healthcare project, which uses generative artificial intelligence (GenAI) to improve patient experiences by reducing time to care and staffing shortages, significantly improving experiences for patients and providers. Article content The Calabrio Canada-led CareAI initiative is the result of Calabrio's Wysdom (the original partner in the CareAI initiative) acquisition. In the first year, CareAI addressed the 53% of patient inquiries tied to long wait times attributed to staffing shortages, reducing costs through automated recommendations. Additionally, the solution enhanced communication and improved efficiency by analyzing patient-provider transcripts for insights into empathy, professionalism and resolution quality. Article content Now in the second year of its partnership with healthcare leaders and DIGITAL, Canada's Global Innovation Cluster for digital technologies, the expansion marks one of the first applications of healthcare-grade Quality Management to GenAI, with models trained to evaluate empathy, safety and clinical effectiveness of the AI agents. With human agents freed up to manage more complex interactions, CareAI equips healthcare organizations with the necessary oversight to deliver compliant, compassionate, high-quality virtual care at scale. Article content 'Healthcare providers and patients deserve safe, easy to understand and timely interactions whether from a human or virtual agent,' said Dave Rhodes, CEO of Calabrio. 'This partnership has allowed us to develop and deploy innovative solutions for patient care contact centers. Calabrio solutions like Auto QM and Trending Topics allow healthcare providers to deliver more consistent, empathetic and high-quality care at scale. These solutions are transforming the healthcare industry by addressing critical challenges with real-world, results-driven innovation.' Article content Calabrio's solutions, specifically designed for healthcare, utilize domain-specific language and patient context to facilitate accurate communication between human and AI agents, to ultimately transform patient call data into proactive quality improvements. Collectively, these advancements establish CareAI as the leader in AI-driven healthcare transformation with significant benefits for healthcare providers such as automated quality assurance, actionable insights from patient conversations, and real-world cost savings and efficiency gains, that drive meaningful enhancements to patient care. Article content About Calabrio Article content Calabrio is a trusted ally to leading brands. The digital foundation of a customer-centric contact center, the Calabrio ONE workforce performance suite, helps enrich and understand human interactions, empowering your contact center as a brand guardian. We maximize agent performance, exceed customer expectations, and boost workforce efficiency using connected data, AI-fueled analytics, automated workforce management, and personalized coaching. Only Calabrio ONE unites workforce optimization (WFO), agent engagement, and business intelligence solutions into a cloud-native, fully integrated suite that adapts to your business. Article content Calabrio, Calabrio ONE and the Calabrio logo are registered trademarks or trademarks of Calabrio, Inc. All other trademarks mentioned in this document are the property of their respective owners. Calabrio operates in Canada under Calabrio Canada, Ltd., based in British Columbia. Article content Article content Article content Article content Article content Article content
Globe and Mail
2 hours ago
- Globe and Mail
WELL Health Reports Record Revenue, Adjusted EBITDA, and Adjusted Net Profit in Q2-2025, Upgrades Guidance, and Delivers First-Ever Quarter With More Than 1 Million Patient Visits in Canada
WELL Health Technologies Corp. (TSX: WELL, OTCQX: WHTCF) (the ' Company ' or ' WELL '), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce its interim consolidated financial results for the quarter ended June 30, 2025. Hamed Shahbazi, Chairman and CEO of WELL commented, 'I am very proud of our performance this quarter as it reflects a very significant milestone in our history with best-ever performances across most of our key financial metrics. We delivered record performances across Revenue, Adjusted EBITDA, Adjusted Net Income, and patient visits. Furthermore, we would have reported best-ever Free Cash Flow Available to Shareholders had we not had elevated cash taxes and capital expenditures due to new investments made in our Canadian clinics, executive health and longevity health portfolios, which have historically delivered excellent returns on capital invested (ROIC). Importantly, we also delivered $17M in IFRS net profit for the quarter demonstrating our ability to deliver on all key adjusted and non-adjusted metrics. I'm also very pleased to commemorate that we delivered more than 1 million patient visits in Canada during the quarter for the first time ever reflecting 38% YoY growth; approximately a third of which came from organic growth. It's important to remember the significance of each of those visits and how vital it can be to a person's health and wellness. This awareness, along with our growing scale and relevance in the healthcare ecosystem, is top of mind for us. We think about it every day as we are committed to making the investments that are designed to help healthcare providers deliver the best care and patient outcomes possible. One positive by-product of our investments is the growing productivity of our providers. The average provider at WELL grew its number of patient visits by 22%. While there are many contributors to this improvement, we believe improved tooling and technology to be one of those key reasons.' Mr. Shahbazi further added, "We are also very pleased to report our first quarter with the inclusion of HEALWELL AI, a company that we helped launch and incubate almost two years ago and in which we took a majority voting control position this past April. Yesterday HEALWELL reported record financial performance along with its first profitable quarter on an Adjusted EBITDA basis and signalled its intent to become a pure-play SaaS and Services company now that it has achieved significant scale in delivering data science and healthcare software expertise to large enterprise customers in 11 countries globally. In parallel, we continue to evaluate strategic alternatives for our U.S. assets to simplify our business and sharpen our focus on our core Canadian operations. Across the WELL ecosystem, our teams are focused on driving sustainable, profitable growth and delivering meaningful impact through technology, innovation, and operational excellence.' Eva Fong, WELL's Chief Financial Officer, commented, 'Our second quarter results demonstrate the strength of our operating model and disciplined approach to capital allocation. Year to date, we have completed fourteen transactions and are pleased to report fifteen signed LOIs representing approximately $134 million in revenues. Our high-quality pipeline of acquisition opportunities mostly includes targets across Canadian Clinics and WELLSTAR. Also, notably our WELLSTAR platform delivered another strong 'Rule of 40' performance with strong organic revenue growth and healthy Adjusted EBITDA margins, while executing on its M&A pipeline. WELLSTAR's goal is to exceed $100 million in revenues next year with continued strong margins and growth metrics. Overall, we remain committed to improving margin profile and operating leverage across the organization, while evaluating strategic opportunities to streamline and optimize our portfolio. With a strong balance sheet and increasing cash generation, we are well-positioned to support long-term growth and return value to shareholders.' Second Quarter 2025 Financial Highlights: WELL achieved record quarterly revenue of $356.7 million in Q2-2025, an increase of 57% compared to revenue of $227.3 million generated in Q2-2024. This growth was mainly driven by organic growth, acquisitions that have occurred over the last twelve months and the addition of $40.5 million of revenue in Q2-2025 from the inclusion of HEALWELL, as per IFRS reporting requirements following the company's execution of a call option to acquire voting shares of HEALWELL on April 1, 2025, relating to our majority voting position with HEALWELL. Excluding the impact of 'CM Deferrals', revenue would have reached $347.0 million, representing a 53% increase compared to the previous year. Adjusted Gross Profit (1) was $158.7 million in Q2-2025, an increase of 73% compared to Adjusted Gross Profit of $91.5 million in Q2-2024. Adjusted Gross Margin (1) percentage was 44.5% during Q2-2025 compared to Adjusted Gross Margin percentage of 40.3% in Q2-2024. The increase in Adjusted Gross Margin percentage was primarily driven by revenue mix and the addition of higher margin HEALWELL revenue, while being offset by the addition of lower margin Provider Staffing revenue from the acquisition of Harmony in January 2025. Adjusted EBITDA (1) was $49.7 million in Q2-2025, an increase of 231% compared to Adjusted EBITDA of $15.0 million in Q2-2024. Excluding the impact of CM Deferrals, Adjusted EBITDA would have reached $40.0 million, representing a 166% increase compared to the previous year. Adjusted EBITDA Attributable to WELL shareholders was $37.5 million in Q2-2025, an increase of 215% compared to Adjusted EBITDA Attributable to WELL shareholders of $11.9 million in Q2-2024. Adjusted Net Income (1) was $25.8 million, or $0.10 per share in Q2-2025, compared to Adjusted Net Income of $4.1 million, or $0.02 per share in Q2-2024. Free Cash Flow Available to Shareholders (or FCFA2S) was $11.7 million in Q2-2025 an increase of 34% compared to FCFA2S of $8.7 million in Q2-2024. Note that FCFA2S was impacted by elevated cash taxes and capital expenditures which were focused on investments in upgrading our clinical portfolio. Segmented Revenue: Canadian Patient Services revenue was $114.5 million in Q2-2025, an increase of 49% compared to $76.7 million in Q2-2024. U.S. Patient Services revenue was $184.8 million in Q2-2025, an increase of 38% compared to $133.7 million in Q2-2024. WELLSTAR, the Company's pure-play SaaS technology subsidiary, achieved revenue of $15.2 million in Q2-2025, an increase of 49% compared to $10.2 million in Q2-2024. WELLSTAR's growth was driven by healthy organic growth and acquisitions. Second Quarter 2025 Patient Visit Metrics: WELL achieved a total of 1.7 million patient visits in Q2-2025, an increase of 21% compared to 1.4 million patient visits in Q2-2024. Canadian Patient Services visits increased 38% while US Patient Services visits decreased 1%, on a year-over-year basis. Notably, the Company achieved over 1 million patient visits across its Canadian operations, a new quarterly milestone. Growth in patient visits over the past year was primarily driven by acquisitions as well as double-digit organic growth, including the clinic absorption program. In addition, WELL achieved over 2.7 million Care Interactions (2) in Q2-2025, representing approximately 10.8 million patient interactions on an annualized run-rate basis. Second Quarter 2025 Business Highlights: On April 1, 2025, the Company and the pre-HEALWELL founders amended the terms of the conditional call option held by the Company to acquire up to 30.8 million Class A Subordinate Voting Shares of HEALWELL at $0.125 per share and 30.8 million Class B Multiple Voting shares of HEALWELL at $0.0001 per share such that it became exercisable, and the Company exercised the call option to acquire such shares for total consideration of $3.9 million. On April 1, 2025, the release conditions were satisfied related to the Company's January 21, 2025, subscription for HEALWELL shares and the Company received 0.5 million Class A voting shares and 0.25 million share purchase warrants with each warrant exercisable into one Class A Subordinate Voting share at $2.50 per share for a period of 36 months in accordance with the terms of the subscription agreement. As of April 1, 2025, the Company held 97.2 million Class A Subordinate Shares and 30.8 million Class B Multiple Voting shares of HEALWELL, representing approximately 37% of the economic interest and approximately 69% of the voting rights in HEALWELL on a non-diluted basis. As a result, the Company obtained control of HEALWELL under IFRS, and accordingly, began to consolidate the financial results of HEALWELL as a subsidiary of the Company effective April 1, 2025. On May 6, 2025, the Company announced the rebranding of its cybersecurity division as CYBERWELL and the appointment of Jeffrey Engle as CEO. CYBERWELL consolidates four firms: Source44, SeekIntoo, Cycura, and Proack Security into a unified cybersecurity company. The division will focus on recurring revenue, acquisitions, and international expansion. WELL noted plans for CYBERWELL to potentially be spun out in the future and serve as a key growth engine. On May 7, 2025, WELLSTAR announced the launch of Nexus AI, a new AI-powered clinical documentation solution available across Canada. The product is initially focused on AI scribing and will expand through partnerships across the WELL ecosystem. Nexus AI is supported by government funding for up to 10,000 providers through Canada Health Infoway's AI Scribe pilot program. On May 28, 2025, the Company announced that subsidiaries of HEALWELL and WELLSTAR, Intrahealth, Pentavere, and OceanMD, were selected as recipients of Canada Health Infoway's 2025 Vendor Innovation Program. The program supports the development and implementation of real-world interoperability solutions aligned with national digital health priorities. The selected projects aim to enhance data quality, care coordination, and access to standardized health information across Canada, with deployments planned in five provinces. Three of the eight recipients are affiliated with the WELL and HEALWELL group. On June 24, 2025, the Company announced the availability of over 45,000 new primary care patient openings across its clinic network in Ontario, Alberta, and Manitoba. The expansion is enabled by investments in physician recruitment, including the onboarding of internationally trained medical graduates, and the implementation of digital infrastructure powered by WELLSTAR Technologies. The Company's National Patient Registration system, supported by OceanMD's eForms, online booking, and automated triage tools, is streamlining access and enabling clinics to accelerate the creation of new patient panels. Events Subsequent to June 30, 2025: On July 8, 2025, the Company announced the completion of two clinic acquisitions in British Columbia, effective July 1, 2025. The acquired clinics include a personalized health clinic in Vancouver and a multidisciplinary clinic in Burnaby, expanding the Company's presence in preventative health and specialty care. On July 8, 2025, the Company announced an expansion and extension of its senior secured credit facility, led by Royal Bank of Canada, increasing total capacity to approximately $200 million and extending the maturity to 2027. The revised facility converts the accordion feature into a revolving credit line, enhancing the Company's financial flexibility to support continued growth. On July 15, 2025, the Company announced that its majority-owned subsidiary, WELLSTAR Technologies Corp., executed three letters of intent for acquisitions expected to contribute approximately $15 million in ARR, $16 million in annual revenue, and over $5 million in Adjusted EBITDA on a run-rate basis. The targets deliver high-margin SaaS solutions that expand WELLSTAR's clinician enablement platform and support its strategy of disciplined, accretive growth. On July 16, 2025 HEALWELL acquired the remaining 49% of Pentavere Research Group Inc. ('Pentavere'), by exercising a call option that it had previously negotiated at the time of its original acquisition of a majority interest in Pentavere in 2023. Pursuant to the call option, HEALWELL acquired all of the remaining issued and outstanding shares of Pentavere for an aggregate purchase price of $13,978 which was satisfied with the issuance of 10,161,562 HEALWELL Class A Subordinate Voting Shares. With 100% ownership of Pentavere, HEALWELL intends to deepen integration between its AI businesses and accelerate commercialization of AI products across healthcare offerings. Outlook: WELL intends to continue its focus on maintaining strong performance, while strategically enhancing operations in the pursuit of organic growth and profitability. WELL is expecting its momentum to continue in the second half of the year across its key business units. WELL's objective is to invest in and achieve significant growth while effectively managing its costs and delivering cash flow to shareholders. Management is pleased to reaffirm its 2025 annual guidance for revenue to be between $1.40 billion to $1.45 billion, representing 52% to 58% annual growth compared to 2024. Excluding the impact of the CM Deferrals, the Company's annual revenue guidance would be between $1.35 billion to $1.40 billion. This annual revenue guidance only includes announced acquisitions; however, WELL expects to be in the upper half of this guidance range with the inclusion of planned acquisitions in the second half of the year. Furthermore, management is pleased to increase its guidance for annual Adjusted EBITDA to be in the upper half of its previously provided guidance of $190 million to $210 million. Excluding the impact of CM Deferrals, the Company is similarly improving its guidance for annual Adjusted EBITDA to be in the upper half of its previously provided guidance of $140 million to $160 million. This improvement of the Company's annual Adjusted EBITDA guidance only includes announced acquisitions. WELL continues to allocate capital thoughtfully in order to activate both organic and inorganic growth. The Company expects to continue to fund its acquisitions from its own cash flow as well as planned divestitures ensuring compounding gains over time on a per share basis. The Company also continues to focus most of its M&A and capital allocation activity in Canada where it is experiencing its strongest returns. Conference Call: WELL will release its Second Quarter 2025 financial results for the period ended June 30, 2025, on Thursday, August 14, 2025. The Company will hold a conference call and simultaneous webcast to discuss its results on the same day at 1:00 pm ET (10:00 am PT). Please use the following dial-in numbers: 1-800-717-1738 (Toll Free) or 1-289-514-5100 (International). The conference call will also be simultaneously webcast and can be accessed at the following audience URL: Selected Unaudited Financial Highlights: Please see SEDAR for complete copies of the Company's condensed interim consolidated financial statements and interim MD&A for the quarter ended June 30, 2025. Quarter ended Six months ended June 30, 2025 March 31, 2025 June 30, 2024 Restated June 30, 2025 June 30, 2024 Restated $'000 $'000 $'000 $'000 $'000 Revenue 356,673 294,137 227,312 650,810 450,795 Cost of sales (excluding depreciation and amortization) (197,934) (176,665) (135,766) (374,599) (265,108) Adjusted Gross Profit (1) 158,739 117,472 91,546 276,211 185,687 Adjusted Gross Margin (1) 44.5% 39.9% 40.3% 42.4% 41.2% Adjusted EBITDA (1) 49,735 27,577 15,045 77,312 35,280 Net income (loss) 16,998 (41,886) 105,574 (24,888) 119,357 Adjusted Net Income (1) 25,771 7,508 4,080 33,279 21,287 Earnings (Loss) per share, basic (in $) 0.05 (0.19) 0.42 (0.14) 0.47 Earnings (Loss) per share, diluted (in $) 0.05 (0.19) 0.41 (0.14) 0.45 Adjusted Net Income per share, basic (in $) 0.10 0.03 0.02 0.13 0.09 Adjusted Net income per share, diluted (in $) 0.10 0.03 0.02 0.13 0.09 Reconciliation of net income (loss) to Adjusted EBITDA (1): Net income (loss) for the period 16,998 (41,886) 105,574 (24,888) 119,357 Depreciation and amortization 25,395 19,546 17,307 44,941 33,867 Income tax expense (recovery) 5,923 (1,229) (6,392) 4,694 (8,832) Interest income (463) (519) (279) (982) (517) Interest expense 12,909 11,406 9,689 24,315 19,230 Rent expense on finance leases (5,407) (4,688) (4,129) (10,095) (8,243) Share-based payments 5,815 2,465 4,765 8,280 10,242 Foreign exchange (gain) loss (1,032) 84 (72) (948) (104) Time-based earnout expense 5,137 215 15 5,352 2,127 Change in fair value of investments (12,751) 35,235 (116,327) 22,484 (130,284) Change in fair value of derivative liability (2,130) - - (2,130) - Gain on disposal of assets and investments - (24) - (24) (11,284) Share of net loss (income) of associates 117 2,380 (177) 2,497 887 Transaction, restructuring and integration costs expensed 2,797 3,870 2,609 6,667 6,091 Legal settlements and defense (recovery) costs (3,573) (31) 1,709 (3,604) 1,990 Other items - 753 753 753 753 Adjusted EBITDA (1) 49,735 27,577 15,045 77,312 35,280 Attributable to WELL shareholders 37,458 20,293 11,914 57,751 27,619 Attributable to Non-controlling interests 12,277 7,284 3,131 19,561 7,661 Adjusted EBITDA (1) WELL Corporate (8,544) (6,519) (5,320) (15,063) (10,087) Canada and others 25,151 18,671 13,032 43,822 27,506 US operations 33,128 15,425 7,333 48,553 17,861 Adjusted EBITDA (1) attributable to WELL shareholders WELL Corporate (8,544) (6,519) (5,320) (15,063) (10,087) Canada and others 22,777 17,209 12,645 39,986 26,892 US operations 23,225 9,603 4,589 32,828 10,814 Adjusted EBITDA (1) attributable to Non-controlling interests Canada and others 2,374 1,462 387 3,836 614 US operations 9,903 5,822 2,744 15,725 7,047 Reconciliation of net income (loss) to Adjusted Net Income (1): Net income (loss) for the period 16,998 (41,886) 105,574 (24,888) 119,357 Amortization of acquired intangible assets 17,432 13,034 11,361 30,466 22,881 Time-based earnout expense 5,137 215 15 5,352 2,127 Share-based payments 5,815 2,465 4,765 8,280 10,242 Change in fair value of investments (12,751) 35,235 (116,327) 22,484 (130,284) Change in fair value of derivative liability (2,130) - - (2,130) - Share of net loss (income) of associates 117 2,380 (177) 2,497 887 Other items - 753 753 753 753 Non-controlling interest included in net income (loss) (4,847) (4,688) (1,884) (9,535) (4,676) Adjusted Net Income (1) 25,771 7,508 4,080 33,279 21,287 Footnotes: Non-GAAP financial measures and ratios. In addition to results reported in accordance with IFRS, the Company uses certain non-GAAP financial measures as supplemental indicators of its financial and operating performance. These non-GAAP financial measures include Adjusted Net Income, Adjusted Net Income Per Share, Adjusted EBITDA, Adjusted Gross Profit, Adjusted Gross Margin, and Adjusted Free Cash Flow. The Company believes these supplementary financial measures reflect the Company's ongoing business in a manner that allows for meaningful period-to-period comparisons and analysis of trends in its business. Adjusted Net Income and Adjusted Net Income per Share The Company defines Adjusted Net Income as net income (loss), after excluding the effects of share-based payments, amortization of acquired intangible assets, time-based earnout expense, change in fair value of investments, change in fair value of derivative liability, non-controlling interests, and revenue precluded from recognition under IFRS 15 that relates to certain patient services revenue that the Company believes should be recognized as revenue based on its contractual relationships. Adjusted Net Income Per Share is Adjusted Net Income divided by weighted average number of shares outstanding. The Company believes that these non-GAAP financial measures provide useful information to analyze our results, enhance a reader's understanding of past financial performance and allow for greater understanding with respect to key metrics used by management in decision making. More specifically, the Company believes Adjusted Net Income is a financial metric that tracks the earning power of the business that is available to WELL shareholders. EBITDA and Adjusted EBITDA EBITDA and Adjusted EBITDA are non-GAAP measures. EBITDA represents net income (loss) before interest, taxes, depreciation, and amortization. The Company defines Adjusted EBITDA as EBITDA (i) less net rent expense on premise leases considered to be finance leases under IFRS and (ii) before transaction, restructuring, and integration costs, time-based earn-out expense, change in fair value of investments, change in fair value of derivative liability, share of loss of associates, foreign exchange gain/loss, and share-based payments, (iii) revenue precluded from recognition under IFRS 15 that relates to certain patient services revenue that the Company believes should be recognized as revenue based on its contractual relationships, and (iv) gains/losses that are not reflective of ongoing operating performance. The Company considers Adjusted EBITDA a financial metric that measures cash that the Company can use to fund working capital requirements, service future interest and principal debt repayments and fund future growth initiatives. EBITDA and Adjusted EBITDA should not be considered alternatives to net income (loss), cash flow from operating activities or other measures of financial performance in accordance with IFRS. Adjusted Gross Profit and Adjusted Gross Margin The Company defines Adjusted Gross Profit as revenue less cost of sales (excluding depreciation and amortization) and Adjusted Gross Margin as adjusted gross profit as a percentage of revenue. Adjusted gross profit and adjusted gross margin should not be construed as an alternative for revenue or net income (loss) determined in accordance with IFRS. The Company does not present gross profit in its consolidated financial statements as it is a non-GAAP financial measure. The Company believes that adjusted gross profit and adjusted gross margin are meaningful metrics that are often used by readers to measure the Company's efficiency of selling its products and services. Adjusted Free Cash Flow The Company defines Adjusted Free Cash Flow Attributable to Shareholders as Adjusted EBITDA Attributable to Shareholders, less cash interest, less cash taxes and less capital expenditures. Adjusted Net income, Adjusted Net Income per Share, Adjusted EBITDA, Adjusted Gross Profit, Adjusted Gross Margin, and Adjusted Free Cash Flow are not recognized measures for financial statement presentation under IFRS and do not have standardized meanings. As such, these measures may not be comparable to similar measures presented by other companies and should be considered as supplements to, and not as substitutes for, or superior to, the corresponding measures calculated in accordance with IFRS. Total Care Interactions are defined as Total Patient Visits plus Technology Interactions plus Billed Provider Hours. WELL HEALTH TECHNOLOGIES CORP. Per: 'Hamed Shahbazi' Hamed Shahbazi Chief Executive Officer, Chairman and Director About WELL Health Technologies Corp. WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 34,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 165 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about WELL, please visit: Forward-Looking Statements This news release may contain 'Forward-Looking Information' within the meaning of applicable Canadian securities laws, including, without limitation: information regarding the Company's goals, strategies and growth plans, including expected acquisitions and divestitures Company and HEALWELL; expectations regarding continued revenue and EBITDA growth; the Company's expectations pertaining to annual guidance for annual revenue and Adjusted EBITDA; the expected benefits and synergies of completed acquisitions; capital allocation plans in the form of more acquisitions or share repurchases; expected patient visits; and the expected financial performance as well as information in the 'Outlook' section herein. Forward-Looking Information are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies. Forward-Looking Information generally can be identified by the use of forward-looking words such as 'may', 'should', 'will', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-Looking Information involve known and unknown risks, uncertainties and other factors that may cause future results, performance, or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by the Forward-Looking Information and the Forward-Looking Information are not guarantees of future performance. WELL's comments expressed or implied by such Forward-Looking Information are subject to a number of risks, uncertainties, and conditions, many of which are outside of WELL 's control, and undue reliance should not be placed on such information. Forward-Looking Information are qualified in their entirety by inherent risks and uncertainties, including: risks regarding the timing and amount of recognition or revenue and earnings; direct and indirect material adverse effects from adverse market conditions; risks inherent in the primary healthcare sector in general; regulatory and legislative changes; that future results may vary from historical results; inability to obtain any requisite future financing on suitable terms; any inability to realize the expected benefits and synergies of acquisitions; that market competition may affect the business, results and financial condition of WELL and other risk factors identified in documents filed by WELL under its profile at including its most recent Annual Information Form and its Management, Discussion and Analysis. Except as required by securities law, WELL does not assume any obligation to update or revise any forward-looking information, whether as a result of new information, events or otherwise. This news release contains future-oriented financial information and financial outlook information (collectively, 'FOFI') about estimated annual run-rate revenue and Adjusted EBITDA, all of which are subject to the same assumptions, risk factors, limitations, and qualifications as set out in the above paragraph. The actual financial results of WELL may vary from the amounts set out herein and such variation may be material. WELL and its management believe that the FOFI has been prepared on a reasonable basis, reflecting management's best estimates and judgments. However, because this information is subjective and subject to numerous risks, it should not be relied on as necessarily indicative of future results. Except as required by applicable securities laws, WELL undertakes no obligation to update such FOFI. FOFI contained in this news release was made as of the date hereof and was provided for the purpose of providing further information about WELL's anticipated future business operations on an annual basis. Readers are cautioned that the FOFI contained in this news release should not be used for purposes other than for which it is disclosed herein.
